New drug JUV-161 tested in healthy volunteers – first step toward muscle disease treatments
NCT ID NCT06918925
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times
Summary
This early-stage study is testing a new drug, JUV-161, in 72 healthy adults to see if it is safe and how the body processes it. Participants receive either the drug or a placebo by injection. The study does not aim to treat any disease, but the results will help plan future trials in people with muscle disorders like myotonic dystrophy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Nucleus Network Pty Ltd
Melbourne, Victoria, 3004, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- First look: can a new drug candidate pass early safety tests in humans?
- A painless, contact-free vibration sensor may detect hidden heart and lung problems
- Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test
- Could a common drug shield the brain from Alzheimer's?